Atreo
Atreo.io revolutionizes client experience with innovative RTSM solutions, supporting 1000+ clinical trials.
Founded
2021Atreo.io revolutionizes client experience with innovative RTSM solutions, supporting 1000+ clinical trials.
Atreo was founded with the mission to revolutionize the client experience in the realm of Randomization and Trial Supply Management (RTSM). The company focuses on providing innovative, customizable RTSM solutions that can be rapidly deployed within 1-2 weeks. Atreo's services cater to a diverse range of clients, from emerging biotech firms to top-tier pharmaceutical companies and Contract Research Organizations (CROs). Their modern and collaborative System Design Experience allows clients to explore and refine fully functional RTSM systems tailored to their specific protocols from day one.
Notable figures affiliated with Atreo include a team with extensive experience across all aspects of RTSM, Clinical Supplies, and Clinical Trials project delivery. The company has supported over 1000 clinical trials, demonstrating significant expertise and impact in the industry. Key achievements include offering 10x testing coverage compared to legacy RTSM providers and unmatched system configurability and agility post-launch. Atreo's innovative approach has set a new standard for client experience in clinical trial management, making a substantial impact on the efficiency and effectiveness of clinical trials globally.
Companies similar to Atreo include 4G Clinical, Endpoint Clinical, Korio and On-Time Trials.
Atreo was founded in 2021.
Atreo's headquarters is located in San Francisco, CA, US.
Atreo's most recent funding round was for $4M (USD) in June 2022.
As of Jun 6, 2022, Atreo has raised a total of $5.8M (USD).
Atreo has 23 employees as of Feb 4, 2024.
korioclinical.com
